Search clinical trials for: Etravirine (TMC125)

Total 241 results

St Stephens Aids Trust

Completed

TMC 125 Blood Levels Study

HIV Infections

United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

Fungal Infection | HIV | AIDS
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial

HIV Infection
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

HIV Infection
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C223: TMC125 in HIV-1 Infected Subjects

HIV Infection
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

HIV-1 | Anti-Retroviral Agents
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV

United States, France, Argentina, Chile, Mexico, Costa Rica, Panama, Brazil, Puerto Rico, Thailand
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.

HIV | Pharmacokinetics
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
University of Colorado, Denver
Gilead Sciences

Completed

Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance

Weight Gain | HIV-1-infection

United States
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Recruiting

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

HIV Infections | Pregnancy Related

United States
IRCCS Eugenio Medea
University of Rome Tor Vergata

Completed

Safety and Efficacy of Etravirine in Friedreich Ataxia Patients (FAEST1)

Friedreich Ataxia

Italy
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

HIV-1 Infection
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

HIV Infections

United States, Brazil, South Africa
Gamaleya Research Institute of Epidemiology and...
MSD Pharmaceuticals LLC

Not yet recruiting

HIV A6 Genome In ART Unsuccessful Patients On DOR (HIV-A6-DOR)

Virus-HIV
Tibotec Pharmaceuticals, Ireland

Completed

TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

HIV-Infections
University of Colorado, Denver

Completed

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

Hepatitis C | HIV

United States
Merck Sharp & Dohme LLC

Completed

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Renal Impairment
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

HIV

United States
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
University of Southern California
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

HIV

United States
National Cancer Institute (NCI)

Terminated

TRC105 for Recurrent Glioblastoma

Glioblastoma Multiforme

United States
St Stephens Aids Trust

Completed

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

HIV

United Kingdom
University of Roma La Sapienza

Recruiting

Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge). (DORAge)

HIV

Italy
National Cancer Institute (NCI)

Completed

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Urothelial Carcinoma | Ureteral Neoplasms | Ureter Cancer | Cancer of the Ureter | Neoplasm, Ureteral

United States
GlaxoSmithKline

Completed

DDI Study of Etravirine and GSK1265744

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Clinique du Quartier Latin
Merck Frosst Canada Ltd.

Unknown

HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

HIV Infections

Canada, Martinique
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Merck Sharp & Dohme LLC

Completed

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

HIV-infected Participants With ESRD Undergoing Routine Hemodialysis

Spain
Chelsea and Westminster NHS Foundation Trust
Merck Sharp & Dohme LLC; Imperial College London; University of Liverpool

Completed

Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

Human Immunodeficiency Virus

United Kingdom
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Germans Trias i Pujol Hospital

Completed

Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression

HIV

Spain
Fundacion Clinic per a la Recerca Biomédica

Active, not recruiting

Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

HIV-1-infection

Spain
ViiV Healthcare
Pfizer

Withdrawn

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Hepatitis B | Hepatitis C, Chronic | Human Immunodeficiency Virus

United States, Canada, Poland
Janssen R&D Ireland

Completed

A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.

Healthy Volunteers

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

HIV-1 Infection
Braintree Laboratories

Completed

A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children

Constipation

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration

Hepatitis C Virus
Merck Sharp & Dohme LLC

Recruiting

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection

United States, Mexico, Russian Federation, South Africa, Thailand
Institut de Médecine et d'Epidémiologie Appliquée...
Merck Sharp & Dohme LLC

Active, not recruiting

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" (DORASPEP)

HIV Infections

France
National Cancer Institute (NCI)

Completed

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Prostate Cancer | Metastatic Castrate Resistant Prostate Cancer

United States
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
University of North Carolina, Chapel Hill
Janssen Pharmaceuticals

Completed

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

HIV Infections

United States
Tracon Pharmaceuticals Inc.

Completed

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States

3

Subscribe